美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

AgomAb Therapeutics

14.65

-1.3500-8.44%

盤後：14.61-0.0378-0.26%17:31 EST

成交量：236.22萬

成交額：3,364.66萬

市值：7.14億

市盈率：- -

高：15.49

開：14.70

低：12.66

收：16.00

52周最高：15.49

52周最低：12.66

股本：4,873.68萬

流通股本：1,250.00萬

量比：- -

換手率：18.90%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：-3.96

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

AgomAb Therapeutics

交易所：

NASDAQ

成立時間：

2017

員工人數：

62

公司地址：

Posthoflei 1/6,Antwerp,Antwerp,Belgium

官網：

http://www.agomab.com

郵編：

2600

電話：

傳真：

- -

簡介：

AgomAb Therapeutics NV最初於2017年4月13日根據比利時法律註冊成立，是一家比利時私人有限責任公司。該公司是一家臨床階段的生物製藥實體，致力於開發針對免疫學和炎症性疾病的創新疾病改善療法，特別專註於存在重大未滿足醫療需求的慢性纖維化疾病。其候選產品旨在針對既定途徑，並使用經過驗證的模式來增強療效，同時最大限度地減少全身毒性，從而解決先前治療的局限性。其使命是創造不僅能解決纖維化，還能恢復器官功能的療法，讓患者過上更充實、更健康的生活。

董事

名稱

職位

David Epstein

Chairman of the Board

Tim Knotnerus

Chief Executive Officer and Executive Director

Angelika Jahreis

Non-Executive Director

Colin Bond

Non-Executive Director

Felice Verduyn van Weegen

Non-Executive Director

Ohad Hammer

Non-Executive Director

股東

名稱

職位

Tim Knotnerus

Chief Executive Officer and Executive Director

Pierre Kemula

Chief Financial Officer

Andrea Saez

Chief Development Officer

Ellen Lefever

General Counsel

Paul van der Horst

Chief Business Officer

Philippe Wiesel

Chief Medical Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/AGMB/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":14.65,"timestamp":1770411600000,"preClose":16,"halted":0,"volume":2362243,"hourTrading":{"tag":"盘后","latestPrice":14.6122,"preClose":14.65,"latestTime":"17:31 EST","volume":45883,"amount":665330.3415549999,"timestamp":1770417061449,"change":-0.0378,"changeRate":-0.00258,"amplitude":0.149768},"delay":0,"changeRate":-0.08437499999999998,"floatShares":12500000,"shares":48736779,"eps":0,"marketStatus":"盤後交易","change":-1.35,"latestTime":"02-06 18:44:00 EST","open":14.7,"high":15.49,"low":12.66,"amount":33646636.517416,"amplitude":0.176875,"askPrice":15.7,"askSize":6,"bidPrice":13.49,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1770426000000},"marketStatusCode":4,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":16,"postHourTrading":{"tag":"盘后","latestPrice":14.6122,"preClose":14.65,"latestTime":"17:31 EST","volume":45883,"amount":665330.3415549999,"timestamp":1770417061449,"change":-0.0378,"changeRate":-0.00258,"amplitude":0.149768},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":12500000,"roa":"--","roe":"--","lyrEps":0,"shares":48736779,"dividePrice":0,"high":15.49,"amplitude":0.176875,"preClose":16,"low":12.66,"week52Low":12.66,"pbRate":"-3.96","week52High":15.49,"institutionHeld":0,"latestPrice":14.65,"committee":0.886792,"eps":0,"divideRate":0,"volume":2362243,"delay":0,"ttmEps":0,"open":14.7,"prevYearClose":16,"fiveDayClose":16,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":563168576,"yearFounded":2017,"employeeNum":62,"address":"Posthoflei 1/6,Antwerp,Antwerp,Belgium","zipCode":"2600","officePhone":"32 3 318 91 70"},"stockCompanyDetail":{"websiteUrl":"http://www.agomab.com","stockEarnings":[{"period":"1week","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"AgomAb Therapeutics NV最初於2017年4月13日根據比利時法律註冊成立，是一家比利時私人有限責任公司。該公司是一家臨床階段的生物製藥實體，致力於開發針對免疫學和炎症性疾病的創新疾病改善療法，特別專註於存在重大未滿足醫療需求的慢性纖維化疾病。其候選產品旨在針對既定途徑，並使用經過驗證的模式來增強療效，同時最大限度地減少全身毒性，從而解決先前治療的局限性。其使命是創造不僅能解決纖維化，還能恢復器官功能的療法，讓患者過上更充實、更健康的生活。","exchange":"NASDAQ","name":"AgomAb Therapeutics","nameEN":"AgomAb Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":{"directors":[{"name":"David Epstein","position":"Chairman of the Board"},{"name":"Tim Knotnerus","position":"Chief Executive Officer and Executive Director"},{"name":"Angelika Jahreis","position":"Non-Executive Director"},{"name":"Colin Bond","position":"Non-Executive Director"},{"name":"Felice Verduyn van Weegen","position":"Non-Executive Director"},{"name":"Ohad Hammer","position":"Non-Executive Director"}],"executives":[{"name":"Tim Knotnerus","position":"Chief Executive Officer and Executive Director"},{"name":"Pierre Kemula","position":"Chief Financial Officer"},{"name":"Andrea Saez","position":"Chief Development Officer"},{"name":"Ellen Lefever","position":"General Counsel"},{"name":"Paul van der Horst","position":"Chief Business Officer"},{"name":"Philippe Wiesel","position":"Chief Medical Officer"}]}}}